In an industry first, all ongoing studies migrated to ³Ô¹Ï±¬ÁÏ EDC from legacy EDC <\/i><\/p>\n
BARCELONA, Spain \u2014 17 Jan. 2024 \u2014<\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced a top 20 biopharma and ³Ô¹Ï±¬ÁÏ Services migrated 25 ongoing clinical studies to ³Ô¹Ï±¬ÁÏ EDC<\/a> from a legacy electronic data capture (EDC) application. This successful migration of an entire core study portfolio \u2013 including a large study with more than 500 research sites and 7,000 patients \u2013 is an important industry first. With migrations complete, the customer plans to use ³Ô¹Ï±¬ÁÏ EDC for all current and future trials globally.<\/p>\n Life sciences companies have historically avoided migrating studies due to technical challenges, complex data models, and risk concerns. ³Ô¹Ï±¬ÁÏ EDC\u2019s proprietary migration capability enables ³Ô¹Ï±¬ÁÏ Services to migrate ongoing studies securely with minimal disruption. With this top 20 biopharma, ³Ô¹Ï±¬ÁÏ EDC was used to migrate more than 55 million data points and five million forms safely and efficiently.<\/p>\n \u201cLocked down legacy systems and perceived risks have made the topic of migrating studies a non-starter,\u201d said Drew Garty, chief technology officer, ³Ô¹Ï±¬ÁÏ CDMS. \u201cBiopharma companies can now reliably migrate ongoing studies from their legacy applications to ³Ô¹Ï±¬ÁÏ EDC with a repeatable approach that can reduce fees, drive standardization, and provide a better site experience.\u201d<\/p>\n ³Ô¹Ï±¬ÁÏ EDC\u2019s migration capability enables customers to decommission legacy EDC systems while advancing clinical data management. To learn more about ³Ô¹Ï±¬ÁÏ EDC, visit veeva.com\/eu\/VaultEDC<\/a>.<\/p>\n About ³Ô¹Ï±¬ÁÏ Systems<\/strong> ³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong> ###<\/p>\n \nContact:<\/strong>
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n
\nJeremy Whittaker
\n³Ô¹Ï±¬ÁÏ Systems
\n+49-695-095-5486
\njeremy.whittaker@veeva.com<\/a>\n<\/p>\n